145 related articles for article (PubMed ID: 9641739)
1. Effects of a proton-pump inhibitor in cystic fibrosis.
Tran TM; Van den Neucker A; Hendriks JJ; Forget P; Forget PP
Acta Paediatr; 1998 May; 87(5):553-8. PubMed ID: 9641739
[TBL] [Abstract][Full Text] [Related]
2. Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis.
Hendriks JJ; Kester AD; Donckerwolcke R; Forget PP; Wouters EF
Pediatr Pulmonol; 2001 Jan; 31(1):59-66. PubMed ID: 11180676
[TBL] [Abstract][Full Text] [Related]
3. Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency?
ter Heide H; Hendriks HJ; Heijmans H; Menheere PP; Spaapen LJ; Bakker JA; Forget PP
J Pediatr Gastroenterol Nutr; 2001 Sep; 33(3):342-5. PubMed ID: 11593135
[TBL] [Abstract][Full Text] [Related]
4. Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients.
Hendriks HJ; van Kreel B; Forget PP
J Pediatr Gastroenterol Nutr; 2001 Sep; 33(3):260-5. PubMed ID: 11593119
[TBL] [Abstract][Full Text] [Related]
5. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes.
Proesmans M; De Boeck K
Eur J Pediatr; 2003 Nov; 162(11):760-3. PubMed ID: 13680386
[TBL] [Abstract][Full Text] [Related]
6. A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease.
Shimizu Y; Dobashi K; Kobayashi S; Ohki I; Tokushima M; Kusano M; Kawamura O; Shimoyama Y; Utsugi M; Sunaga N; Ishizuka T; Mori M
Tohoku J Exp Med; 2006 Jul; 209(3):181-9. PubMed ID: 16778364
[TBL] [Abstract][Full Text] [Related]
7. [A clinical trial of lansoprazole in the treatment of duodenal ulcer].
Pei Y; Wang B; Chen S
Zhonghua Nei Ke Za Zhi; 1995 Sep; 34(9):606-8. PubMed ID: 8697927
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
9. Lansoprazole: in the management of gastroesophageal reflux disease in children.
Scott LJ
Paediatr Drugs; 2003; 5(1):57-61; discussion 62. PubMed ID: 12513106
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
Sharma VK
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
[TBL] [Abstract][Full Text] [Related]
11. Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study.
Ekström P; Carling L; Unge P; Anker-Hansen O; Sjöstedt S; Sellström H
Scand J Gastroenterol; 1995 Mar; 30(3):210-5. PubMed ID: 7770708
[TBL] [Abstract][Full Text] [Related]
12. Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
Masubuchi N; Hakusui H; Okazaki O
Biochem Pharmacol; 1997 Dec; 54(11):1225-31. PubMed ID: 9416973
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole--another proton pump inhibitor.
Drug Ther Bull; 1995 May; 33(5):36-7. PubMed ID: 7587993
[No Abstract] [Full Text] [Related]
14. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer.
Yamamoto I; Fukuda Y; Okui M; Tamura K; Shimoyama T
J Clin Gastroenterol; 1995; 20 Suppl 1():S38-42. PubMed ID: 7673613
[TBL] [Abstract][Full Text] [Related]
16. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
17. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
18. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
Croom KF; Scott LJ
Drugs; 2005; 65(15):2129-35; discussion 2136-7. PubMed ID: 16225368
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
[TBL] [Abstract][Full Text] [Related]
20. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.
Altintas E; Sezgin O; Ulu O; Aydin O; Camdeviren H
World J Gastroenterol; 2004 Jun; 10(11):1656-8. PubMed ID: 15162544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
